Patents by Inventor Tine WYSEURE

Tine WYSEURE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Dual targeting of TAFI and PAI-1
    Patent number: 10239953
    Abstract: Disclosed herein is a bispecific inhibitor for use in treating thrombotic disorders, such as acute thrombotic disorders like stroke and thromboembolism. The bispecific inhibitor is based on monoclonal antibodies targeting TAFI and PAI-1, and shows efficacy in the presence or the absence of plasminogen activators such as tissue-type plasminogen activator (tPA).
    Type: Grant
    Filed: February 9, 2015
    Date of Patent: March 26, 2019
    Assignees: KATHOLIEKE UNIVERSITEIT LEUVEN, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ DE CAEN BASSE NORMANDIE, CENTRE HOSPITALIER UNVIERSITAIRE DE CAEN
    Inventors: Paul Declerck, Simon De Meyer, Nick Geukens, Ann Gils, Marina Rubio, Denis Vivien, Tine Wyseure
  • DUAL TARGETING OF TAFI AND PAI-1
    Publication number: 20170253664
    Abstract: Disclosed herein is a bispecific inhibitor for use in treating thrombotic disorders, such as acute thrombotic disorders like stroke and thromboembolism. The bispecific inhibitor is based on monoclonal antibodies targeting TAFI and PAI-1, and shows efficacy in the presence or the absence of plasminogen activators such as tissue-type plasminogen activator (tPA).
    Type: Application
    Filed: February 9, 2015
    Publication date: September 7, 2017
    Inventors: Paul DECLERCK, Simon DE MEYER, Nick GEUKENS, Ann GILS, Marina RUBIO, Denis VIVIEN, Tine WYSEURE
  • DUAL TARGETING OF TAFI AND PAI-1
    Publication number: 20160347859
    Abstract: Disclosed herein is a bispecific inhibitor for use in treating thrombotic disorders, such as acute thrombotic disorders like stroke and thromboembolism. The bispecific inhibitor is based on monoclonal antibodies targeting TAFI and PAI-1, and shows efficacy in the presence or the absence of plasminogen activators such as tissue-type plasminogen activator (tPA).
    Type: Application
    Filed: February 9, 2015
    Publication date: December 1, 2016
    Inventors: Paul DECLERCK, Simon DE MEYER, Nick GEUKENS, Ann GILS, Marina RUBIO, Denis VIVIEN, Tine WYSEURE